Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bladder cancer combo aims to stop recurrence

NCT ID NCT05943106

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a combination of two treatments—the standard BCG therapy and an immunotherapy drug called durvalumab—for adults with high-risk, early-stage bladder cancer that hasn't spread into the muscle wall. The goal is to see if this combination is safe and more effective at preventing the cancer from coming back than BCG alone. It will involve about 100 participants in the US who have not received BCG treatment before.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85054, United States

  • Research Site

    Little Rock, Arkansas, 72211, United States

  • Research Site

    San Diego, California, 92123, United States

  • Research Site

    Lakewood, Colorado, 80228, United States

  • Research Site

    Hialeah, Florida, 33016, United States

  • Research Site

    Jacksonville, Florida, 32209, United States

  • Research Site

    Greenwood, Indiana, 46143, United States

  • Research Site

    Wichita, Kansas, 67226, United States

  • Research Site

    Baltimore, Maryland, 21203, United States

  • Research Site

    Hanover, Maryland, 21076, United States

  • Research Site

    Royal Oak, Michigan, 48073, United States

  • Research Site

    Troy, Michigan, 48084, United States

  • Research Site

    Syracuse, New York, 13210, United States

  • Research Site

    Cincinnati, Ohio, 45212, United States

  • Research Site

    Bala-Cynwyd, Pennsylvania, 19004-1017, United States

  • Research Site

    Myrtle Beach, South Carolina, 29572, United States

  • Research Site

    Nashville, Tennessee, 37209, United States

  • Research Site

    Austin, Texas, 78759, United States

  • Research Site

    Spokane, Washington, 99202, United States

Conditions

Explore the condition pages connected to this study.

NON-MUSCLE-INVASIVE BLADDER CANCER